Key facts
- StapleBio’s last known valuation is $10.8M.
- It has raised $4.2M; the latest was Early Stage VC ($3.0M) in May 2024.
- Notable investors include Mitsubishi UFJ Capital, Diamond Medino Capital, Higin Capital, KSP (Kawasaki), Sumisho Pharma International — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for StapleBio
- ·The full record, as it builds
Funding rounds
No funding rounds for StapleBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About StapleBio
Operator of a nucleic acid-based therapeutic platform intended to modulate target protein expression levels for treating cancer, CNS disorders, autoimmune diseases, viral infections, and rare hereditary conditions. The company offers Staple oligomer technology that selectively hybridizes to target mRNA and induces G-quadruplex structures, enabling drug developers and researchers to regulate gene expression precisely.
- Sector
- Healthcare
- HQ
- Kumamoto, Japan
- Founded
- 2021
- Website
- staplebio.jp/
- Ownership
- Privately Held (backing)
StapleBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in StapleBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on StapleBio in its N-PORT filings yet. We sweep new filings monthly.